A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity

Summary: The poor prognosis of patients with recurrent or refractory T cell malignancies emphasizes the need for improved immunotherapies. CD5 is a characteristic marker of malignant T cells and is expressed on almost all normal T cells. Therefore, for treating T cell malignancies, focusing on natur...

Полное описание

Библиографические подробности

Главные авторы:	Chen Yang, Ping Wang, Mingjun Yang, Huaqing Lu, Qizhong Lu, Zongliang Zhang, Zeng Wang, Zhixiong Zhu, Hexian Li, Wanqin Zeng, Zhengyu Yu, Meng Li, Lizhou Zhao, Bo Ling, Wei Wang, Hai Yi, Yisong Xiong, Ting Niu, Aiping Tong
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2025-10-01
Серии:	Cell Reports Medicine
Предметы:	T cell malignancies CD5 natural killer cells CD16a nanobody immunotherapy
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2666379125004823
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!